key: cord-0997010-zhe7qtzs authors: Melo, Paulo; Barbosa, João Malta; Jardim, Luis; Carrilho, Eunice; Portugal, Jaime title: COVID-19 Management in Clinical Dental Care. Part I: Epidemiology, Public Health Implications, and Risk Assessment date: 2021-02-10 journal: Int Dent J DOI: 10.1016/j.identj.2021.01.015 sha: 419562ce9a206fdaa2931035c0dc0e76d5ccd9b5 doc_id: 997010 cord_uid: zhe7qtzs COVID-19, a viral disease declared as a pandemic by the World Health Organization in March 2020, has posed great changes to many sectors of society across the globe. The virulence and rapid dissemination have forced the adoption of strict public health measures in most countries, which, collaterally, resulted in economic hardship. This paper is the first in a series of three and aims to contextualize the COVID-19 clinical impact for the dental profession. It presents the epidemiological conditions of SARS-CoV-2, namely, its modes of transmission, incubation and transmissibility period, signs and symptoms, immunity, immunological tests, and risk management in dental care. Individuals in dental care settings are exposed to three potential sources of contamination with COVID-19: close interpersonal contacts (<1 meter), contact with saliva, and aerosol-generating dental procedures. Thus, we propose a risk management model for the provision of dental care, depending on the epidemiological setting, the patient's characteristics, and the type of procedures performed in the office environment. Although herd immunity seems hard to achieve, a significant number of people has been infected throughout the first 9 months of the pandemic and the vaccination has been implemented, which means that there will be a growing number of presumable “immune” individuals that might not require precautions that differ from those before COVID-19. In conclusion, dental care professionals may manage their risk by following the proposed model, which considers the recommendations by local and international health authorities, thus providing a safe environment for both professionals and patients. Since the beginning of this century, three novel coronaviruses (CoV) capable of infecting human beings have caused a significant number of infections which led to the declaration of a public health emergency. In November 2002, from the Guangdong province in China, came the first reports of patients with symptoms of a new disease that would come to be known as the severe acute respiratory syndrome (SARS). A novel coronavirus responsible for this disease (SARS-CoV) was isolated in February 2003. 1 The SARS epidemic affected 26 countries on 5 continents (Asia, Oceania, North America, Europe, and Africa), resulting in 8096 reported infections and 774 deaths, until containment of the outbreak was declared in July 2003 by the World Health Organization (WHO). 2, 3 The case fatality rate associated with SARS was 9.6%. 3 Since 2004, no new cases of SARS have been reported worldwide. 4 Ten years later, in June 2012, Saudi Arabia reported the first cases of a new disease later named Middle East respiratory syndrome (MERS). The pathogen responsible for this disease, a novel coronavirus (MERS-CoV), was isolated in September 2012. 5, 6 Since then, several outbreaks have been reported, with cases diagnosed in 27 countries. However, approximately 80% of cases were reported in Saudi Arabia, and the cases identified outside the Middle East have usually been associated with travelers infected in that region before returning to their original country. 7, 8 As of January 2020, 2519 cases of MERS had been confirmed, resulting in 866 deaths, which corresponds to a case fatality rate of 37.1%. 9 Recently, in December 2019, the city of Wuhan, in the province of Hubei in China, became the epicenter of an outbreak of pneumonia of unknown etiology. [10] [11] [12] On January 7, 2020, a novel virus was isolated from patients with that disease, and the International Committee on Taxonomy of Viruses named it "severe acute respiratory syndrome coronavirus 2" (SARS-CoV-2) in February. In March, the WHO named the disease as COVID- 19. 13,14 Initially, the SARS-CoV-2 epidemic remained limited to China, with most cases being reported in the province of Hubei, and only isolated cases being detected in neighboring countries, such as Thailand, Japan, and the Republic of Korea. 15 However, in the following months, the disease spread worldwide. On January 23, the United States of America (USA) reported its first case. 16 On January 25, the first cases were reported in Australia and France -presumably, the first European country to be affected by this disease. 17 On February 15, WHO reported the first case in the African continent (in Egypt). 18 On February 27, the first case of this novel coronavirus appeared in South America (in Brazil). 19 During March 2020, with the reported number of new cases decreasing in China, the epicenter of the epidemic shifted to Europe, with the largest outbreaks of cases first in Italy and then in Spain. On March 12, with the disease reported in more than 100 countries, COVID-19 was officially declared as a pandemic by the WHO. 20 During April, May and June, the epicenter of the epidemic shifted once again, this time to the Americas, mainly the USA, Brazil and Chile. The following months, some countries that had the epidemic under control faced new foci or the second wave with a significant increase in the number of deaths This trend resulted in an impressive outcome making COVID-19 the leading cause of death in some countries. 21 As of December 27, 2020, 79, Such differences seem to be related to geographic and social differences of the countries in those regions, including the methods used for counting cases, the mean age of the population, the intensity of the outbreak, the type of containment measures adopted and how soon they were adopted. 23 It has been found that patients older than 65 years have a higher risk of death if they become infected. 24 The COVID-19 CFR has also been higher in individuals with a previous chronic disease, which correspond to more than half reaching 90% of the cases of infection. [25] [26] [27] Most COVID-19 confirmed cases have been in patients over 30 years old, with more than 90% being over 45 years old. 28, 29 Determining the severity of COVID-19 is critical for implementing mitigation strategies and planning for healthcare needs as the pandemic evolves. However, the CFR is a poor measure of the mortality risk since a large number of cases are asymptomatic or present with mild symptoms and testing has not been performed on the entire population. 30 A better way to estimate the mortality risk is the infection fatality rate (IFR, in % -number of deaths from COVID-19 / total number of infected individuals). Published research data on COVID-19 showed overall IFR converging around 0.2%-1.6% in the first months of the pandemic. 31 Moreover, the estimated age-specific IFR is very low for children and younger adults (e.g., 0.002% at age 10 and 0.01% at age 25) and increases progressively to 0.4% at age 55, 1.4% at age 65, 4.6% at age 75, and 15% at age 85. [32] [33] [34] Due to its infection rate and lethality, the COVID-19 pandemic has become one of the greatest public health challenges of this century, as no treatment or vaccine were known or available for some time. The main problem has been the rate of COVID-19 patients that require admission in intensive care units (UCI) and particularly mechanical ventilation, since some healthcare services might not be able to match the demand, which may ultimately increase the percentage of infected individuals who die, raising the IFR. Thus, infection control measures are essential to prevent viral propagation and help control the epidemic. 35 With the COVID-19 pandemic's geographic expression progressively widening across the globe, several countries have implemented strict measures to reduce interpersonal COVID-19 transmission. In the health sector, particularly in the provision of dental care, the implementation of additional measures to contain the possible transmission of the disease was considered essential. 36 Currently, suspected COVID-19 positive cases present with certain symptoms including: acute respiratory infection (sudden onset of fever, dry cough, or respiratory distress) without other etiology that explains the clinical signs and symptoms and with history of traveling or living in areas with active community transmission in the 14 days before symptoms onset; acute respiratory infection and contact with a confirmed or probable case of COVID-19 in the 14 days prior to the onset of symptoms; or severe acute respiratory infection, requiring hospitalization, without other etiology that could explain the clinical presentation. 37 This paper is the first from a series of three. With these three papers, we aim to contextualize the virus SARS-CoV-2 and the disease COVID-19 for the dental profession, focusing on risk management in dental care, COVID-19's repercussion in dental settings, personal protective equipment (PPE) selection and proper use, and measures to be applied in the dental office. This first paper aims to contextualize the clinical impact of the disease for the dental profession. It presents the epidemiological conditions of COVID-19, namely, its modes of transmission, incubation and transmissibility period, signs and symptoms, immunity, immunological tests, and risk management in dental care. The origin of the virus responsible for COVID-19 -SARS-CoV-2, is still being debated and investigated. Despite some controversy and although not yet fully clarified, the comparative analysis of genomic data suggests that the outbreak may have begun with a zoonotic animalto-human transmission, with a pangolin that was infected by a bat in a market in Wuhan and later infecting a human being. 38 It was then followed by human-to-human transmission, which led to its spread, starting in the city of Wuhan in China. 39 SARS-CoV-2 is highly contagious and is transmitted via respiratory droplets, by direct contact with infected people, or by contact with contaminated surfaces and objects. 40 The respiratory droplets expelled from the nose or mouth when an infected individual coughs, sneezes or speaks, may come in contact with the oral, nasal, or conjunctiva mucosae of an individual standing nearby, thus resulting in transmission of the disease. 40,41 Contamination may also occur indirectly by hand contact with contaminated surfaces followed by hands in contact with the face. 40, 42 Research has shown that, in an external environment, such as inert dry surfaces, SARS-CoV-2 might survive up to 72 hours on plastic and stainless steel, 24 hours on paper or cardboard, and less than 4 hours on copper surfaces, depending on the temperature and humidity. In watery environments, the virus might survive several days. 43 Clinical and virologic studies suggest that the viral load is particularly high in the superior respiratory tract, nose, and throat in the first three days after the onset of symptoms. 44, 45 However, the virus has also been found in several body fluids, including feces, and, thus, the risk of fecal-oral transmission cannot be dismissed. 42, [46] [47] [48] The viral load needed for SARS-CoV-2 transmission is approximately 1000 viral particles per minute (vp/min). As a reference, when breathing, approximately 20 vp/min are expelled, when talking, 200 vp/min, and when coughing or sneezing, 200 million vp /min. The transmission risk is very low in outside spaces and on surfaces. 49 It is known that the SARS-CoV-2 viral load peaks approximately at symptom onset, with a viral load similar to that of influenza. 50 Conversely, SARS-CoV and MERS-CoV peak at around 10 days or during the second week after symptom onset. This viral load profile behavior of SARS-CoV-2 suggests that it can be easily transmissible at an early stage of infection. 51 Older people may have higher viral loads. 50 It has been suggested that, although there is no clear evidence that SARS-CoV-2 can be transmitted to humans through pet cats and dogs, these can be contaminated by their owners with COVID-19. 52,53 A different SARS-CoV-2 strain has also been reported in mink on farms in multiple countries. 54 Usually asymptomatic or with slight respiratory and digestive symptoms, pets may act as asymptomatic dispersers of SARS-CoV-2. 52, 53 SARS-CoV-2 presents as a sphere of 0.06 to 0.14 µm in diameter and may be found in saliva droplets, which can remain in the air for long periods. 55, 56 Therefore, airborne transmission is a possibility, mainly in closed areas, in some aerosol-generating procedures (AGP), such as those occurring in tracheal intubation, bronchoscopy, non-invasive ventilation, tracheotomy, manual ventilation prior to intubation, and cardiopulmonary resuscitation, among others. 57, 58 There is no evidence of SARS-CoV-2 transmission through AGP in dental care environments, but it remains a possibility. 59 Since SARS-CoV-2 is an RNA virus, this type of virus tends to mutate more easily. Three different strains were initially detected in different continents: A -Australia and USA; B -China and Europe; and C -Europe via Singapura and fifteen mutations. Another mutation (D614G) emerged in Europe in February and became the dominant form of the virus throughout the world. 60 Since then, different strains have developed without changing its virulence. In November, a new strain was found out in the UK and in South Africa. The UK strain seems to spread 70% faster, which may lead to a speed-up on the virus spread. 61 This strain presents seventeen potentially important mutations including changes in the spike protein. 61 Incubation period and transmission The mean incubation period for COVID-19, from exposure to the virus to the onset of symptoms, is 5 to 6 days on average, although it may be as short as 2 days and as long as 14 days. [62] [63] [64] The high viral load found mainly in the first three days after the onset of symptoms seems to explain why COVID-19 is transmitted mostly by symptomatic patients. 44, 45 Nevertheless, considering that some individuals may test positive for COVID-19 a few days before developing symptoms, and based on some clinical reports, transmission in a presymptomatic stage (the incubation period) is also a possibility. 39, [65] [66] [67] [68] [69] [70] [71] Lastly, although there are reports of truly asymptomatic cases confirmed by laboratory tests, there is no evidence of asymptomatic transmission (when the infecting person has no symptoms throughout the course of the disease), 72 because that is difficult to quantify. However, this does not exclude the risk of COVID-19 transmission by asymptomatic carriers that may be 3-25 times lower than for those with symptoms. 63, 69, 73, 74 As in most infections, clinical signs and symptoms may be mild or absent (asymptomatic carrier), and patients who have been exposed are advised to remain under medical observation and quarantine or isolation for at least 14 days. 37 Clinical signs and symptoms The clinical signs and symptoms of COVID-19 vary widely, from asymptomatic or subsymptomatic presentations to a flu-like syndrome, 43 to severe respiratory insufficiency requiring mechanical ventilation in ICUs, which may ultimately lead to death. 75 The most common signs and symptoms are fever, dry cough and tiredness. Less common symptoms, such as aches and pains (headache and muscular pain), sore throat, expectoration, rhinorrhea, hemoptysis, anosmia (loss of the sense of smell), ageusia (loss of taste), diarrhea, and vomit, may also be present. 76 Of those, anosmia and ageusia might be referred by dental patients during their visit to the dentist and provide to the dentist a reason to suspect of COVID-19. In more complex situations, the clinical presentation may be moderate to severe disease with pneumonia, dyspnea, increased respiratory rate, and decreased blood oxygen saturation; or critical disease with respiratory insufficiency, acute cardiac injury, septic shock, and multiple organ failure, which more frequently results in death. 26 These more severe cases seem to be associated with massive inflammatory reactions in the endothelium of several organs, including the lungs and the heart. [77] [78] [79] On the other hand, the high incidence of thromboembolic events suggests that COVID-19-induced coagulopathy plays an important role in the disease outcome. [79] [80] [81] Patients infected with coronaviruses associated with severe respiratory disease, such as COVID-19, have shown inappropriate activation of the coagulation cascade and subsequent formation of systemic or intra-alveolar fibrin clots, which may result from an attempt of the prothrombotic response to prevent diffuse alveolar hemorrhage that instead causes clot formation, negatively affecting recovery and survival. 82, 83 Platelet and fibrin thrombi found in small pulmonary vessels of patients who died from this disease may explain the severe hypoxemia that is characteristic of the acute respiratory distress syndrome associated with the more severe forms of COVID-19. 78, 80 Most patients seem to develop SARS-CoV-2-induced pulmonary changes, with diffuse alveolar damage, leading to acute respiratory insufficiency. 84 Pneumonia, which can be combined with pulmonary embolism/emboli, have been identified as the main cause of death. 81, 85 Additionally, it is clear that bacterial superinfections are common in patients suffering from a severe case of COVID-19. 86 Poor oral hygiene should be considered a risk to COVID-19 complications in patients with diabetes, hypertension or cardiovascular disease because they are more prone to have biofilms with a higher percentage of pathogens. 86 In these particular cases, oral hygiene should be improved during a COVID-19 infection in order to reduce the bacterial load in the mouth and the risk of a bacterial superinfection. 86 Although the combination of the previously described signs and symptoms with lung imaging may suggest COVID-19 infection, the final diagnosis depends on the confirmation by a laboratory test. 87 Samples obtained via an oral or nasal swab, as well as from the trachea and nasopharynx, pulmonary tissue, saliva, expectoration, feces, and blood can be isolated and used for detection of COVID-19 using molecular diagnostic techniques. 88 The nature and duration of potential immunity after contact with the virus remains unknown. Advancing scientific knowledge on this particular aspect of infection may lead to significant changes in the management of the disease within a community. Herd immunity to SARS-CoV-2, with over 60% of the population infected, is believed to be achievable but depends directly on whether a robust immune response is generated after contact with the virus. At present, it is estimated that only 12% of the world population has come to contact with the virus, but it can be predicted that this is 6.2 times larger than the estimated rate, 89 -a percentage far below the 60% target. A potential solution for the pandemic might be the development and deployment of a vaccine. Until now the average time to develop a vaccine was 10 years, and the faster one was the Ebola vaccine that was produced in 5 years. Several companies early started the development of scientific tests to produce a vaccine within an acceptable time frame. 90 Due to great investments and compromise between companies, governments and regulatory agencies, five vaccines became available in less than a year. The first vaccines to be administered in the US and Europe were the Pfizer/BioNTech and Moderna vaccines. Both are lipid nanoparticle-formulated, nucleoside-modified RNA vaccines that encode the prefusion stabilized SARS-CoV-2 full-length spike protein with similar vaccine efficacy (around 95%) and low incidence of serious adverse events. 91, 92 Spike proteins are thus produced by host cells, which mount an immune response to those proteins. Vaccines using a viral vector are also available, such as AstraZeneca/Oxford, the Chinese Sinovac and the Russian Sputnic V vaccines, in which modified viruses deliver the genetic code for antigens in order to stimulate the body to develop immunity. Overall efficacy of the Oxford vaccine was reported at 70.4% (62.1% in participants who received two standard doses, and 90.0% in participants who received a low dose followed by a standard dose) with an acceptable safety profile. 93 Vaccination has already started in several countries, with priority to the high-risk groups and is expected to continue throughout the year. Advances in hospital-based COVID-19 care and therapeutic agents authorized by national agencies such as monoclonal antibodies Remdesivir, and dexamethasone treatments seem to show effectivity for SARS-CoV-2, although some variants appear to be more resistant to monoclonal antibody treatment. 94, 95 However, up to this moment, prevention is still the main approach to controlling the pandemic. Two types of tests are available to detect viral infections: reverse transcription-quantitative polymerase chain reaction (RT-qPCR) assays and serological immunoassays that detect viralspecific antibodies (IgM and IgG) or viral antigens, typically part of a surface protein. Presently, RT-qPCR and antigen tests are used for ongoing infection detection for SARS-CoV-2. These tests has been essential to screen and identify infected people. RT-qPCR diagnostic tests can be quick, providing results after 1-8 hours and WHO's interim guidelines indicates its use to confirm COVID-19 suspected cases. 96, 97 Nevertheless, due to the incubation period, the technique used to obtain samples, their transportation, and the analysis method, these tests have relatively low sensitivity -from 60 to 80%, which may lead to many false-negative results. 98 In situations where RT-qPCR diagnostic tests are unavailable or time constrains are a problem, antigen-detecting Rapid Diagnostic Tests (Ag-RDT) can be used in the diagnosis of SARS CoV-2. Ag-RDT compared to a RT-qPCR appears to be highly variable, ranging from 0-94% but specificity is consistently reported to be high (>97%). 99, 100 Immunological methods, such as serologic tests (IgG and IgM), may be used to detect whether an individual has been exposed to SARS-CoV-2. 87 These tests required more time to be developed because they require knowledge of the structure of the proteins that form the viral coat. Highly specific serological tests sensitive for SARS-CoV-2 antibodies, with a precision higher than 95%, are currently available using several SARS-CoV-2 proteins. 101 The clinical sensitivity of the serological tests for anti-SARS-CoV-2 IgM and IgG antibodies, when used in combination, is 98.5%, with a clinical specificity of 98.7%. A positive result for IgM may reflect recent exposure to the virus, 3 to 10 days after the onset of symptoms, while a positive result for IgG may represent an exposure 10 to 20 days after onset of symptoms. During the convalescence stage, the IgG antibody may increase approximately four-fold compared with the acute stage. 64, 98, 102 The SARS-CoV-2 spike protein (S protein), which makes the serological tests more unique and lowers the odds of cross-reactivity, is used for differentiation from other coronaviruses. However, assessment of acquired immunity is further complicated by lack of clarity related to cross-reactivity to IgG directed towards other coronaviruses. 97, [103] [104] [105] [106] The use of saliva for the diagnosis of COVID-19 has been a worldwide focus of study and interest. This fact is related to the sensitivity of the salivary sample being similar to that of respiratory samples. On the other hand, the ease of collecting allows the risk of viral transmission for health professionals to be reduced and can be self-collected without the need for trained and/or specialized people, saving medical human resources in the context of pandemics. 107, 108 Although rRT-PCR represents the reference standard for molecular diagnosis in salivary samples, the time spent makes it difficult to use when a population screening program is intended to be carried out. However, rapid salivary antigen tests can be used in pandemic outbreak containment programs. These tests have a main application outside the hospital context due to their ease of use and speed in providing results (30 to 60 minutes), requiring no specialists. 107 Coronaviruses possess very specific characteristics that explain their tropism for the host cells. 109 The SARS-CoV-2 shares the typical structure of coronaviruses, with spike proteins (S protein) in its external membrane, allowing for host cell penetration. The coronavirus S protein links to the receptor of the human angiotensin-converting enzyme 2 (ACE2), facilitating the entry of the virus in target cells. 110 ACE2 is anchored to the plasma membrane of cells on a number of tissues. In the oral cavity, cells of the salivary glands, tongue, and oral epithelium have receptors for ACE2. Salivary glands, in particular, seem to be an early target for SARS-CoV, and therefore will likely be involved in SARS-CoV-2 infection, which may explain its transmission by asymptomatic patients. 36, 56, [110] [111] [112] [113] [114] Despite scarce scientific evidence, procedures conducted in the oral healthcare environment that involve the use of ultrasonic or rotative instrumentation under irrigation, or three way air/water spray, capable of generating aerosols, may potentiate airborne transmission of SARS-CoV-2. 115 Droplets <5μm in diameter are referred to as droplet nuclei or aerosols and may stay in the air for long time, while droplets >5 will quickly fall over the surfaces. 116 Aerosols and droplets generated by their use in the presence of the patient's saliva, blood and other secretions may contaminate the surrounding environment. 36, 75, 117 As such, considering the risk and the stage of community transmission of COVID-19, it is essential to adjust infection control measures in order to protect patients and dental care providers, and thus help contain or mitigate the disease. Such measures should be adjusted to the particularities of each local setting, as well as the level of risk associated with each visit, considering the patient's characteristics and the procedures to be performed. Considering the currently known modes of transmission, the dental care environment presents three sources for potential contamination by SARS-CoV-2: close interpersonal contact (<1 meter), contact with saliva, and AGP. 36, [118] [119] [120] Thus, considering the characteristics of delivery of dental care, and transmission of the virus, every in-office dental visit should be considered as a risk for the involved healthcare personnel, regardless of the procedures to be performed. Therefore, patients must be contacted one day before the visit to confirm no COVID-19 symptoms and measures to again confirm no COVID-19 symptoms on the day of the visit should be implemented, including a temperature check. The relative risk associated with each visit will depend on three factors: the epidemiological setting (prevalence of infection in the area at the time when care is delivered), the patient's individual characteristics, and the type of procedures to be performed. A pandemic is a worldwide dissemination of a disease for which most of the population does not have immunity. 121 It is an enormous public health concern and epidemiology plays a fundamental role in the development and adoption of containment strategies. The type and intensity of control measures vary at the different stages of a pandemic. Although each pandemic has specific characteristics, the WHO has described six phases of pandemic development for an influenza-like pandemic followed by a post peak and a post pandemic periods (Table 1) . 122 Though there are some differences between an influenza pandemic and the current coronavirus pandemic, the propagation periods and the measures to be adopted may be equivalent and considered in the context of dental practice. It is advisable to closely follow the recommendations issued by each country's health authorities, as well as by global health organizations, such as the WHO, the European Centre for Disease Prevention and Control (ECDC), and the Centers for Disease Control and Prevention (CDC). The relative risk based on each patient should be interpreted considering the particular susceptibility of some population subgroups for COVID-19. Four main subgroups should be considered: asymptomatic patients, high-risk patients, COVID-19 patients, and COVID-19 recovered patients. Asymptomatic patients are primarily healthy adults and children that, if infected, pose a higher risk of contaminating others since their infection is generally not detected due to the absence of symptoms. 39, 65, 123 High-risk patients are those with a higher risk of developing severe forms of the disease, specifically individuals older than 65 years, with comorbidities, and/or pregnant women (Table 2) . 24, 39, 62, 64, 65, 118, [124] [125] [126] [127] [128] [129] [130] [131] [132] [133] Therefore, the office schedule should be managed in a way that limits the contact the high risk patients have with other patients throughout the pandemic. Risk of dental care procedures No in-office dental care procedure or visit should be considered "risk-free" as the patient cannot wear a facial barrier when care is provided. In the presence of a disease where herd immunity is yet unknown, a low viral load may be sufficient to transmit the infection between the patient and dental care professionals. 36, 117, 127, 134, 135 On the other hand, direct contact with saliva and respiratory secretions is a risk factor common to every in-office dental visit and might be further worsened by treatment duration and AGP. 57, 58, 136 The AGPs production during each of the procedures described in Table 3 should also be taken in consideration. It is not the same situation working in the upper second molar or in the upper central incisor. The procedures conducted in the dental care environment may be classified, according to their risk, as follows (Table 3) b. Procedures in a clinical environment (conducted inside the operatory room and associated with patients' examination and treatment, affecting both the dentist and auxiliary staff) without AGP -no ultrasonic, rotation instruments and/or three-way air/water spray used; 3. High risk: Procedures in a clinical environment with AGP -dental procedures that use spray-generating equipment such as ultrasonic, rotation instruments, and/or three-way air/water spray. The most common AGP are prophylaxis with ultrasonic scaler and polishing; periodontal treatment with ultrasonic scaler; any kind of dental preparation with high-or low-speed handpieces; direct and indirect restoration and polishing; definitive cementation of crown or bridge; mechanical endodontic treatment and surgical implant placement. Besides the risk of surface contamination within the dental treatment room, these visits also present a higher risk of airborne contamination and consequent contamination of surfaces further away from the dental chair. 36, 120 These factors should be considered during the current pandemic, as they will influence the visit scheduling and preparation, the level of PPE that the dentist and auxiliary staff should wear, the treatment approach, and cleaning and disinfection procedures. Assuming that COVID-19 will remain a pandemic disease for more than a year, with more than one wave, it is important to define strategies that attend to the specific epidemiologic situation at the moment in a way that allows dental offices to work safely. In this paper and the following two in this series, the aim is to develop a risk management model for different phases of the COVID-19 pandemic, which considers all patients as potentially infected. This model was developed considering the specifics of different dental care procedures while simultaneously ensuring the protection and safety of both the professionals and patients. During the first months of the pandemic there was a level of scientific uncertainty regarding the behavior of this new virus, and significant public alarm. The adoption and implementation of the first protocols for management of clinical dental care in COVID-19 may now be seen as excessive, in this sense the current protocols turn this management more reasonable and is expected to turn it even more as soon as a significant percentage of the population gets vaccinated. CONCLUSIONS SARS-CoV-2 and the resulting COVID-19 pandemic present a series of public health challenges that affect dental practice. Three potential sources of contamination are pertinent in this context: close interpersonal interaction (<1 meter), contact with saliva, and/or AGP. As such, the relative risk of in-office visits depends on the epidemiological setting at a specific time and in a geographic region, patient characteristics, and the type of procedures to be performed. The dental team is responsible for managing these considerations, following the recommendations made by local health authorities. These steps will minimize the risk of viral infection in the dental environment. Epidemiology and cause of severe acute respiratory syndrome (SARS) in Guangdong, People's Republic of China Update 96 -Taiwan, China: SARS transmission interrupted in last outbreak area. World Health Organization Summary of probable SARS cases with onset of illness from 1 Centers for Disease Control and Prevention Isolation of a Novel Coronavirus from a Man with Pneumonia in Saudi Arabia MERS coronavirus: diagnostics, epidemiology and transmission Middle East respiratory syndrome coronavirus (MERS-CoV). World Health Organization Middle East Respiratory Syndrome Coronavirus (MERS-CoV) origin and animal reservoir World Health Organization Novel Coronavirus (2019-nCoV) -Situation Report -1. World Health Organization Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The Lancet Novel Coronavirus (2019-nCoV) -Situation Report -2. World Health Organization Novel Coronavirus (2019-nCoV) -Situation Report -3. World Health Organization. January23 Novel Coronavirus (2019-nCoV) -Situation Report -5. World Health Organization COVID-19) -Situation Report -26. World Health Organization COVID-19) -Situation Report -38. World Health Organization COVID-19) -Situation Report -52. World Health Organization COVID-19 as the leading cause of death in the United States COVID-19 Weekly Epidemiological Update. World Health Organization Explaining among -country variation in COVID-19 case fatality rate Risk factors of fatal outcome in hospitalized subjects with coronavirus disease 2019 from a nationwide analysis in China COVID-19, SARS and MERS: are they closely related? The SARS-CoV-2 outbreak: What we know COVID-19 death comorbidities in Canada. StatCan COVID-19: Data to Insights for a Better Canada Weekly Updates by Select Demographic and Geographic Characteristics. Provisional Death Counts for Coronavirus Disease (COVID-19) Potential Biases in Estimating Absolute and Relative Case-Fatality Risks during Outbreaks A systematic review and meta-analysis of published research data on COVID-19 infection fatality rates Estimates of the severity of coronavirus disease 2019: a model-based analysis Estimating the infection and case fatality ratio for coronavirus disease (COVID-19) using age-adjusted data from the outbreak on the Diamond Princess cruise ship Assessing the age specificity of infection fatality rates for COVID-19: systematic review, mata-analysis, and public policy implications Surveillance strategies for COVID-19 human infection. World Health Organization Transmission routes of 2019-nCoV and controls in dental practice COVID-19) pandemic: increased transmission in the EU/EEA and the UK -seventh update. European Centre for Disease Prevention and Control Probable Pangolin Origin of SARS-CoV-2 Associated with the COVID-19 Outbreak A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster 2019-nCoV transmission through the ocular surface must not be ignored. The Lancet Surface Environmental, and Personal Protective Equipment Contamination by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) From a Symptomatic Patient Maxillo-Facial Surgery and Oral Surgery (SFSCMFCO). Practitioners specialized in oral health and coronavirus disease 2019: Professional guidelines from the French society of stomatology, maxillofacial surgery and oral surgery, to form a common front against the infectious risk Viral dynamics in mild and severe cases of COVID-19. The Lancet Infect Dis Virological assessment of hospitalized patients with COVID-2019 First Case of 2019 Novel Coronavirus in the United States Detection of SARS-CoV-2 in Different Types of Clinical Specimens A Case Series of children with 2019 novel coronavirus infection: clinical and epidemiological features The Risks -Know Them -Avoid Them Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study Suppression of a SARS-CoV-2 outbreak in the Italian municipality of Vo' A Critical Needs Assessment for Research in Companion Animals and Livestock Following the Pandemic of COVID-19 in Humans. Vector Borne Zoonotic Dis Can companion animals become infected with Covid-19? World Organisation for Animal Health Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1 Saliva: potential diagnostic value and transmission of 2019-nCoV Nosocomial Transmission of Emerging Viruses via Aerosol-Generating Medical Procedures Aerosol Generating Procedures and Risk of Transmission of Acute Respiratory Infections to Healthcare Workers: A Systematic Review Clinical evidence based review and recommendations of aerosol generating medical procedures in otolaryngology -head and neck surgery during the COVID-19 pandemic Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus Incubation period of 2019 novel coronavirus (2019-nCoV) infections among travellers from Wuhan, China The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application Transmission of 2019-nCoV Infection from an Asymptomatic Contact in Germany A Familial Cluster of Infection Associated With the Novel Coronavirus Indicating Possible Person-to-Person Transmission During the Incubation Period Potential Presymptomatic Transmission of SARS-CoV-2 Presymptomatic Transmission of SARS-CoV-2 -Singapore Occurrence and transmission potential of asymptomatic and presymptomatic SARS-CoV-2 infections: A living systematic review and meta-analysis Estimating the extent of asymptomatic COVID-19 and its potential for community transmission: Systematic review and meta-analysis Virology, transmission, and pathogenesis of SARS-CoV-2 Post-lockdown SARS-CoV-2 nucleic acid screening in nearly ten million residents of Wuhan, China Household Transmission of SARS-CoV-2: A Systematic Review and Meta-analysis What do we know about SARS-CoV-2 transmission? A systematic review and meta-analysis of the secondary attack rate and associated risk factors COVID-19 Transmission in Dental Practice: Brief Review of Preventive Measures in Italy World Health Organization Endothelial cell infection and endotheliitis in COVID-19. The Lancet Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study Incidence of thrombotic complications in critically ill ICU patients with COVID-19 Pulmonary postmortem findings in a series of COVID-19 cases from northern Italy: a two-centre descriptive study Autopsy Findings and Venous Thromboembolism in Patients With COVID-19: A Prospective Cohort Study Coagulation disorders in coronavirus infected patients: COVID-19, SARS-CoV-1, MERS-CoV and lessons from the past Prominent changes in blood coagulation of patients with SARS-CoV-2 infection Pulmonary Arterial Thrombosis in COVID-19 With Fatal Outcome: Results From a Prospective, Single-Center Dying with SARS-CoV-2 infection-an autopsy study of the first consecutive Oral hygiene risk factor Measures for diagnosing and treating infections by a novel coronavirus responsible for a pneumonia outbreak originating in Wuhan Laboratory Testing Strategy Recommendations for COVID-19: Interim Guidance Robust estimates of the true (population) infection rate for COVID-19: a backcasting approach The COVID-19 vaccine development landscape Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK Deaths From COVID-19 Update: FDA Authorizes Monoclonal Antibodies for Treatment of COVID-19. U. S. Food & Drug Administration Laboratory testing for coronavirus disease (COVID-19) in suspected human cases: interim guidance. World Health Organization COVID-19 testing strategies and objectives. European Centre for Disease Prevention and Control ) 98. Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (Trial Version 7). National Health Commission State Administration of Traditional Chinese Medicine SARSCoV-2 Diagnostic Pipeline. Foundation for Innovative New Diagnostics Antigen-detection in the diagnosis of SARS-CoV-2 infection using rapid immunoassays: interim guidance Clinical Performance of Two SARS-CoV-2 Serologic Assays Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019 Antibody responses to SARS-CoV-2 in COVID-19 patients: the perspective application of serological tests in clinical practice Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibody Responses in Coronavirus Disease Evaluation of Nucleocapsid and Spike Protein-based ELISAs for detecting antibodies against SARS-CoV-2 The dynamics of humoral immune responses following SARS-CoV-2 infection and the potential for reinfection Diagnostic Salivary Tests for SARS-CoV-2 Salivary diagnostics of the novel coronavirus SARS-CoV-2 (COVID-19) Receptor-binding domain of SARS-CoV spike protein induces highly potent neutralizing antibodies: implication for developing subunit vaccine SARS and MERS: recent insights into emerging coronaviruses Angiotensin-Converting Enzyme 2 (ACE2) in Disease Pathogenesis Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis Epithelial cells lining salivary gland ducts are early target cells of severe acute respiratory syndrome coronavirus infection in the upper respiratory tracts of rhesus macaques Salivary Glands: Potential Reservoirs for COVID-19 Asymptomatic Infection The First Few X Cases and Contacts (FFX) Investigation Protocol for Coronavirus Disease 2019 (COVID-19). World Health Organization Transmission of SARS-CoV-2: Implications for infection prevention precautions: Scientific brief Coronavirus Disease 2019 (COVID-19): Emerging and Future Challenges for Dental and Oral Medicine Prevalence of comorbidities and its effects in coronavirus disease 2019 patients: A systematic review and meta-analysis High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa Aerosol and Surface Distribution of Severe Acute Respiratory Syndrome Coronavirus 2 in Hospital Wards The classical definition of a pandemic is not elusive Pandemic Phase Descriptions and Main Actions by Phase. Pandemic Influenza Preparedness and Response -WHO guidance document. World Health Organization Epidemiology and transmission of COVID-19 in 391 cases and 1286 of their close contacts in Shenzhen, China: a retrospective cohort study Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study COVID-19 and Cancer: Lessons From a Pooled Meta-Analysis Population-level COVID-19 mortality risk for non-elderly individuals overall and for non-elderly individuals without underlying diseases in pandemic epicenters Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China Novel Coronavirus (2019-nCoV) Infection in Humans: A Scoping Review and Meta-Analysis Maternal and perinatal outcomes with COVID-19: A systematic review of 108 pregnancies Coronavirus disease 2019 during pregnancy: a systematic review of reported cases People with certain medical conditions Covid-19: Why are age and obesity risk factors four serious disease? High prevalence of obesity in severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) requiring invasive mechanical ventilation Severe acute respiratory syndrome (SARS) and the GDP. Part II: implications for GDPs Possible aerosol transmission of COVID-19 and special precautions in dentistry Role of two-way airflow owing to temperature difference in severe acute respiratory syndrome transmission: revisiting the largest nosocomial severe acute respiratory syndrome outbreak in Hong Kong The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.